17 Feb 2023

The approval of Ximluci® in Europe positions Xbrane as a leading global biosimilar developer

14 Feb 2023

Invitation to presentation of Xbrane Biopharma’s Year-end report 2022 on February 17, 2023.

17 Jan 2023

STADA and Xbrane obtain British approval for Ximluci® (ranibizumab) biosimilar referencing Lucentis®

15 Dec 2022

XBRANE PROVIDES AN UPDATE ON RANIBIZUMAB BIOSIMILAR CANDIDATE FDA FILING

11 Nov 2022

STADA and Xbrane secure EU approval for Ximluci® (ranibizumab) biosimilar referencing Lucentis®

31 Oct 2022

Change of number of shares and votes in Xbrane

28 Oct 2022

Presentation of Xbrane Biopharma’s interim report January – September 2022 on October 28, 2022

28 Oct 2022

Xbrane Biopharma releases interim report for January – September 2022

26 Oct 2022

Invitation to presentation of Xbrane Biopharma’s interim report January – September 2022 on October 28, 2022

20 Oct 2022

Xbrane Biopharma presents Nomination Committee

18 Oct 2022

Xbrane has carried out a directed share issue raising gross proceeds of approximately SEK 170 million

18 Oct 2022

Xbrane announces intention to carry out a directed share issue

19 Sep 2022

By reason of the imminent launch of Ximluci® in Europe, Xbrane Biopharma AB invites to a Capital Markets Day on September 22, 2022

16 Sep 2022

STADA and Xbrane welcome EMA positive opinion for ranibizumab biosimilar candidate Ximluci

07 Sep 2022

Welcome to Xbrane’s Capital Markets Day, including a unique visit to the new research lab, on September 22, 2022